stockrow
Saturday 7 November 2026
Export CRVS’s income statement to Excel — free account
Corvus Pharmaceuticals, Inc.
CRVS Healthcare Biotechnology
- EPS
- −90.0%
- Free cash flow
- −171.3%
Quarter to June 2026, against a year earlier
10.57
0.84
+8.63%
Follow CRVS
Alert me
Corvus Pharmaceuticals, Inc. (CRVS) P/E ratio
Corvus Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 88.5× (October 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 88.5×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRVS Corvus Pharmaceuticals, Inc. | n/m |
| ALMS Alumis Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| PRME Prime Medicine, Inc. compare | n/m |
| AKTS Aktis Oncology, Inc. compare | n/m |
| SNDX Syndax Pharmaceuticals, Inc. compare | n/m |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.4× |
| MGTX MeiraGTx Holdings PLC compare | 11.8× |
| LTGO Latigo Biotherapeutics Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)